These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 9813666

  • 21. Single amino acid change in Tat determines the different rates of replication of two sequential HIV-1 isolates.
    LeGuern M, Shioda T, Levy JA, Cheng-Mayer C.
    Virology; 1993 Aug; 195(2):441-7. PubMed ID: 8337822
    [Abstract] [Full Text] [Related]

  • 22. Blocking HIV replication by targeting Tat protein.
    Hamy F, Gelus N, Zeller M, Lazdins JL, Bailly C, Klimkait T.
    Chem Biol; 2000 Sep; 7(9):669-76. PubMed ID: 10980447
    [Abstract] [Full Text] [Related]

  • 23. Transactivation of heterologous promoters by HIV-1 tat.
    Han P, Brown R, Barsoum J.
    Nucleic Acids Res; 1991 Dec; 19(25):7225-9. PubMed ID: 1662814
    [Abstract] [Full Text] [Related]

  • 24. Exon2 of HIV-2 Tat contributes to transactivation of the HIV-2 LTR by increasing binding affinity to HIV-2 TAR RNA.
    Rhim H, Rice AP.
    Nucleic Acids Res; 1994 Oct 25; 22(21):4405-13. PubMed ID: 7971271
    [Abstract] [Full Text] [Related]

  • 25. Optimal Tat-mediated activation of the HIV-1 LTR promoter requires a full-length TAR RNA hairpin.
    Verhoef K, Tijms M, Berkhout B.
    Nucleic Acids Res; 1997 Feb 01; 25(3):496-502. PubMed ID: 9016587
    [Abstract] [Full Text] [Related]

  • 26. A nucleolar TAR decoy inhibitor of HIV-1 replication.
    Michienzi A, Li S, Zaia JA, Rossi JJ.
    Proc Natl Acad Sci U S A; 2002 Oct 29; 99(22):14047-52. PubMed ID: 12376617
    [Abstract] [Full Text] [Related]

  • 27. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter.
    Brès V, Kiernan RE, Linares LK, Chable-Bessia C, Plechakova O, Tréand C, Emiliani S, Peloponese JM, Jeang KT, Coux O, Scheffner M, Benkirane M.
    Nat Cell Biol; 2003 Aug 29; 5(8):754-61. PubMed ID: 12883554
    [Abstract] [Full Text] [Related]

  • 28. Brain-derived human immunodeficiency virus-1 Tat exerts differential effects on LTR transactivation and neuroimmune activation.
    Boven LA, Noorbakhsh F, Bouma G, van der Zee R, Vargas DL, Pardo C, McArthur JC, Nottet HS, Power C.
    J Neurovirol; 2007 Apr 29; 13(2):173-84. PubMed ID: 17505986
    [Abstract] [Full Text] [Related]

  • 29. S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation.
    Daelemans D, Esté JA, Witvrouw M, Pannecouque C, Jonckheere H, Aquaro S, Perno CF, De Clercq E, Vandamme AM.
    Mol Pharmacol; 1997 Dec 29; 52(6):1157-63. PubMed ID: 9396786
    [Abstract] [Full Text] [Related]

  • 30. Transiently transfected and stably integrated HIV-1 LTR responds differentially to the silencing activity of the Krüppel-associated box (KRAB) transcriptional repressor domain.
    Rossi C, Gibellini D, Barbanti-Brodano G, Betti M, Boarini C, Pengue G, Lania L, Caputo A.
    J Med Virol; 1999 Jul 29; 58(3):264-72. PubMed ID: 10447422
    [Abstract] [Full Text] [Related]

  • 31. Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties.
    Demirhan I, Chandra A, Sarin PS, Hasselmayer O, Hofmann D, Chandra P.
    Anticancer Res; 2000 Jul 29; 20(4):2513-7. PubMed ID: 10953320
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of HIV derived lentiviral production by TAR RNA binding domain of TAT protein.
    Mi MY, Zhang J, He Y.
    Retrovirology; 2005 Nov 17; 2():71. PubMed ID: 16293193
    [Abstract] [Full Text] [Related]

  • 33. Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients.
    Rossi C, Balboni PG, Betti M, Marconi PC, Bozzini R, Grossi MP, Barbanti-Brodano G, Caputo A.
    Gene Ther; 1997 Nov 17; 4(11):1261-9. PubMed ID: 9425451
    [Abstract] [Full Text] [Related]

  • 34. Phosphorylation of HIV Tat by PKR increases interaction with TAR RNA and enhances transcription.
    Endo-Munoz L, Warby T, Harrich D, McMillan NA.
    Virol J; 2005 Feb 28; 2():17. PubMed ID: 15737233
    [Abstract] [Full Text] [Related]

  • 35. Replication of human immunodeficiency viruses engineered with heterologous Tat-transactivation response element interactions.
    Xie B, Wainberg MA, Frankel AD.
    J Virol; 2003 Feb 28; 77(3):1984-91. PubMed ID: 12525632
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine.
    Jiang MC, Lin JK, Chen SS.
    Biochem Biophys Res Commun; 1996 Sep 04; 226(1):1-7. PubMed ID: 8806583
    [Abstract] [Full Text] [Related]

  • 37. Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.
    Southgate C, Zapp ML, Green MR.
    Nature; 1990 Jun 14; 345(6276):640-2. PubMed ID: 2190099
    [Abstract] [Full Text] [Related]

  • 38. Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region.
    Xie B, Invernizzi CF, Richard S, Wainberg MA.
    J Virol; 2007 Apr 14; 81(8):4226-34. PubMed ID: 17267505
    [Abstract] [Full Text] [Related]

  • 39. Differential effects of I kappa B molecules on Tat-mediated transactivation of HIV-1 LTR.
    Harhaj E, Blaney J, Millhouse S, Sun SC.
    Virology; 1996 Feb 01; 216(1):284-7. PubMed ID: 8615004
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.